Alex Duggan
Chief Executive Officer
Current roles
Alex Duggan joined the Company as Interim Chief Executive Officer in August 2025 and joined on a permanent basis in November 2025.
Past roles
Chief Commercial and Corporate Development Officer at Alliance Pharmaceuticals, a UK-based consumer healthcare company (previously listed on AIM). He has held multiple leadership positions within consumer healthcare organisations and served as a Board Member of the Proprietary Association of Great Britain (PAGB), the association representing manufacturers of branded over-the-counter medicines and medical devices.
Brings to the Board
Over 30 years of experience in Consumer Healthcare and Prescription sectors, having successfully scaled global businesses across Europe, Asia, North America and Latin America.
Angela Hildreth
Finance Director, Chief Operating Officer and Company Secretary
Current roles
Angela Hildreth leads the Group’s finance, HR and IT functions, drives operational and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters.
Past roles
Senior financial roles in a diverse range of industries, including seven years as UK Finance Director at Shield Therapeutics plc (quoted on AIM). She was also an Independent Non-Executive Director and Chair of the Audit Committee at AIM-listed Aptamer plc.
Brings to the Board
Over 15 years of strategic and operational financial experience of developing and commercialising pharmaceutical and healthcare products.
Ken James
Executive Director and Head of R&D
Current roles
Ken James is the Head of R&D. He oversees the development, regulatory, quality and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.
Past roles
Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.
Brings to the Board
Over 40 years’ experience in the research, development and commercialisation of consumer healthcare products.
Andrew Unitt
Non-Executive Chairman
Current Roles
Andrew Unitt served as an Independent Non-Executive Director. In 2025, he assumed the role of Non-Executive Chairman. He is Chair of the Nominations Committee and is also a member of the Remuneration Committee and the Audit Committee.
Past Roles
Chief Financial Officer at the University of Nottingham until 2016. Andrew spent eleven years at Boots plc, where he was Managing Director and Finance Director for four years of Boots Healthcare International, its over-the-counter medicines business. He has worked as an independent Non-Executive Director for both public and private companies for the last twelve years.
Brings to the Board
Over 20 years of experience as a Non-Executive Director and Finance Director in a wide range of industries with strong financial experience and OTC market expertise.
Roy Davis
Senior Independent Non-Executive Director
Current Roles
Roy Davis is a Senior Independent Non-Executive Director and Chair of the Remuneration Committee and of the Audit Committee. He is a member of the Nominations Committee. Roy is also a Non-Executive Chair at Inspiration Healthcare Group plc, Foster and Freeman (the trading name of the Galton group of companies) and Surgical Innovations plc. He is also a Senior Advisor at Moore Walker Partners.
Past Roles
Leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc and Gyrus Group plc and Non-Executive Chair at Medica Group plc.
Brings to the Board
Over 35 years of commercial experience including in medical devices companies and strategic consulting and has a proven track record of successfully scaling companies and delivering substantial value for shareholders.